Bajaj Healthcare Ltd

Bajaj Healthcare Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed below reflect the company’s current position as of 02 February 2026, providing investors with the latest insights into its performance and outlook.

Bajaj Healthcare Ltd commenced trading today with a significant gap up, opening 7.78% higher than its previous close, signalling a robust start amid positive market sentiment. The stock outperformed its sector and broader market indices, maintaining momentum through a volatile session.

Bajaj Healthcare Ltd’s shares declined to a fresh 52-week low of Rs.336.25 on 27 Jan 2026, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical company’s stock has now recorded a seven-day consecutive fall, accumulating a loss of 14.62% over this period, reflecting persistent pressures within the Pharmaceuticals & Biotechnology sector.

Bajaj Healthcare Ltd’s shares declined to a fresh 52-week low of Rs.355.75 on 23 Jan 2026, marking a significant downturn amid a six-day losing streak that has seen the stock shed 9.62% in value. This decline contrasts sharply with broader market trends, as the Sensex trades near its 52-week high, highlighting sector-specific pressures within the Pharmaceuticals & Biotechnology industry.

Bajaj Healthcare Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 22 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Bajaj Healthcare Ltd’s shares declined to a fresh 52-week low of Rs 372.2 on 20 Jan 2026, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical company’s stock has underperformed both its sector and the broader market, reflecting persistent pressures on its valuation and market sentiment.

Bajaj Healthcare Ltd’s shares declined to a fresh 52-week low of Rs.383 on 12 Jan 2026, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical and biotechnology company’s stock has underperformed its sector and broader market indices, reflecting persistent challenges in its financial and market performance.

Bajaj Healthcare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 06 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 January 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Bajaj Healthcare Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a complex outlook. Despite a modest daily price gain of 1.16%, the stock remains under pressure from bearish moving averages and mixed signals from momentum oscillators, reflecting ongoing challenges in the Pharmaceuticals & Biotechnology sector.

Bajaj Healthcare Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. Despite a modest daily price change, the stock’s technical parameters reveal growing downside risks amid a challenging market environment for the Pharmaceuticals & Biotechnology sector.

Bajaj Healthcare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 December 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 28 December 2025, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Bajaj Healthcare has experienced a subtle shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook, reflecting nuanced changes in key technical indicators. Despite a modest uptick in daily price, the stock’s broader trend remains cautious amid mixed signals from momentum oscillators and moving averages.

Bajaj Healthcare has reached a new 52-week low price of Rs.394.1, marking a significant decline amid broader sector and market movements. The stock has underperformed the Pharmaceuticals & Biotechnology sector and continues to trade below all key moving averages, reflecting ongoing pressures on its market valuation.

Bajaj Healthcare’s recent market activity reveals a notable shift in price momentum, with technical indicators signalling a transition towards a bearish trend. The stock’s performance contrasts with broader market indices, reflecting sector-specific pressures and evolving investor sentiment within the Pharmaceuticals & Biotechnology industry.

Bajaj Healthcare has experienced a revision in its market assessment following a detailed review of its financial performance, valuation metrics, technical indicators, and quality parameters. While the company shows signs of operational strength in recent quarters, longer-term fundamentals and market trends continue to present challenges for investors in the Pharmaceuticals & Biotechnology sector.

Bajaj Healthcare has experienced a subtle shift in its technical momentum, reflecting a complex interplay of market indicators amid a challenging pharmaceutical sector landscape. Recent evaluation adjustments highlight a transition from a predominantly bearish stance to a mildly bearish outlook, underscoring nuanced changes in price momentum and technical signals.

Bajaj Healthcare has reached a new 52-week low of Rs.398, marking a significant price level for the pharmaceutical company as it navigates a challenging market environment. Despite a recent two-day gain, the stock opened sharply lower today and touched this intraday low amid broader sector and market dynamics.